Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)

Market Cap	11.59B +11.7%
Revenue (ttm)	1.09B +15.9%
Net Income	425.83M +35.2%
EPS	0.81 +35.2%
Shares Out	523.58M
PE Ratio	27.21
Forward PE	25.58
Dividend	0.25 (1.11%)
Ex-Dividend Date	Jan 20, 2026

Volume	6,713,100
Open	23.80
Previous Close	22.50
Day's Range	21.94 - 23.80
52-Week Range	19.28 - 35.84
Beta	0.46
Analysts	Buy
Price Target	38.26 (+72.89%)
Earnings Date	Aug 21, 2026

About SHE:300357

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines. The company was founded in 2002 and is headquartered in Huzhou, China.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2002
• Employees: 1,808
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300357

Financial Performance

In 2025, SHE:300357's revenue was 1.06 billion, an increase of 14.81% compared to the previous year's 925.39 million. Earnings were 380.94 million, an increase of 19.86%.